Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Ipca Laboratories Limited, a pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, CIS, and Australasia. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company also provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, hematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. It also exports its products worldwide. The company was incorporated in 1949 and is based in Mumbai, India.

Revenue projections:

Revenue projections for IPCALAB
Revenue projections for IPCALAB

Investors are expected to be cautious with IPCALAB, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 2.627000
forwardPE 25.511347
debtToEquity 16.246000
earningsGrowth 0.136000
revenueGrowth 0.105000
grossMargins 0.689190
operatingMargins 0.146320
trailingEps 35.190000
forwardEps 47.850000

IPCALAB's current ratio of 2.627, indicating that the company can meet its short-term debt obligations with ease. This high liquidity level is a positive sign, as IPCALAB has enough cash and current assets to handle its immediate liabilities comfortably.
IPCALAB's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
IPCALAB's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests IPCALAB maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
Ipca Laboratories Limited's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that Ipca Laboratories Limited will continue to grow its operations, driven by increasing profits and revenue.
IPCALAB's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights IPCALAB's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for IPCALAB
Price projections for IPCALAB

Ipca Laboratories Limited's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.

Insider Transactions:

Insider Transactions for IPCALAB
Insider Transactions for IPCALAB


1 IPCALAB stock sales were completed, with market price of 1513.199951171875.No sell transactions took place in the period under consideration.IPCALAB has seen more buys than sells at its current price levels, which may suggest optimism among investors. This buying trend could indicate that the market expects a favorable performance for the stock in the near future.

Recommendation changes over time:

Recommendations trend for IPCALAB
Recommendations trend for IPCALAB


Analysts' buy bias for IPCALAB signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to IPCALAB, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.